(Q38786707)

6 September 2017

1 reference

title

From tumour heterogeneity to advances in precision treatment of colorectal cancer (English)

1 reference

6 September 2017

1 reference

1 reference

Cornelis J A Punt

1

1 reference

6 September 2017

Miriam Koopman

series ordinal

2

1 reference

6 September 2017

Louis Vermeulen

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

6 December 2016

1 reference

Nature Reviews Clinical Oncology

6 September 2017

published in

1 reference

6 September 2017

volume

14

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

235-246

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2016.171

6 September 2017

exact match

0 references

cites work

Defining stem cell dynamics in models of intestinal tumor initiation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Molecular origins of cancer: Molecular basis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A genetic model for colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Serrated neoplasia-role in colorectal carcinogenesis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Microsatellite instability in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Chemotherapy with preoperative radiotherapy in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Systemic therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Is there a difference in survival between right- versus left-sided colon cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Genetic prognostic and predictive markers in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Association between KRAS mutation and lung metastasis in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Microenvironmental regulation of stem cells in intestinal homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Dissecting cancer heterogeneity--an unsupervised classification approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The consensus molecular subtypes of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A review of excision repair cross-complementation group 1 in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The genomic landscape of response to EGFR blockade in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Wnt addiction of genetically defined cancers reversed by PORCN inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Recurrent R-spondin fusions in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

RSPO fusion transcripts in colorectal cancer in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Cancer heterogeneity--a multifaceted view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The developing cancer stem-cell model: clinical challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A Big Bang model of human colorectal tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Application of Evolutionary Principles to Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Identification and expansion of human colon-cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Colorectal cancer stem cells: from the crypt to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Cancer stem cell niche: the place to be

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Prospective derivation of a living organoid biobank of colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Histological and molecular evaluation of patient-derived colorectal cancer explants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Clonality, Founder Mutations, and Field Cancerization in Human Ulcerative Colitis–Associated Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Molecular genetics of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Moyamoya disease and moyamoya syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.171

Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27922044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27922044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BRAFMutation in Metastatic Colorectal Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27922044

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2016.171

1 reference

Dimensions Publication ID

6 September 2017

1051200513

0 references

1 reference